İnflamatuar barsak hastalıklarında kötü metabolik durum göstergesi olarak HDL/ürik asit oranının değerlendirilmesi
Yükleniyor...
Tarih
2022
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Necmettin Erbakan Üniversitesi Meram Tıp Fakültesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: İnflamatuar barsak hastalıklarında kötü metabolik durum göstergesi olarak HDL/Ürik asit oranının çalışılması amaçlanmıştır.
Yöntem: Çalışmamızda Necmettin Erbakan Üniversitesi Meram Tıp Fakültesi gastroenteroloji kliniği ile genel dahiliye kliniğine Temmuz 2021 ve mayıs 2022 tarihleri arasında başvuran İBH tanılı hastalar ile herhangi bir ek hastalığı olmayan ve fonksiyonel şikayetler ile başvuran hastalar dahil edildi. Hastalar sosyodemografik özellikler, klinik ve laboratuar parametreleri açısından retrospektif olarak tarandı.
Bulgular: Çalışmaya 72’si ülseratif kolit (ÜK) , 26’sı crohn tanısı olan ve 102’si inflamatuar bağırsak hastalığı olmayan toplam 200 katılımcı dahil edildi. Hastaların %56,10’u (n=55) kontrol grubunun ise %43,10’u (n=44) erkekti. Hastaların yaş ortalaması 41,52 ± 13,95 yıl, kontrol grubunun 38,62 ± 14,20 yıl olarak kaydedildi. Ülseratif kolit, crohn ve kontrol grupları arasında cinsiyet, yaş ve vücut kitle indeksi (BMI) dağılımı istatistiki olarak benzer bulundu (p>0,05). Hasta grubunun %76,50’si( n=72) remisyonda, %23,50’si (n=23) atakta olarak tespit edildi. Hastalık süresi ÜK hastalarında ortalama 6,87 ± 5,18 yıl, crohn hastalarında ise 6,30 ± 3,90 yıl olarak belirlendi. Hastaların %29,60’ının (n=29) aktif şikâyeti vardı. ÜK hastalarının %2,80’inde (n=2), crohn hastalarının %30,80’inde (n=8) cerrahi öyküsü vardı. HDL/Ürik Asit oranında hasta ve kontrol grupları ile atak ve remisyon grupları arasında istatistiki olarak anlamlı bir fark saptanmadı (p>0,05). Çalışmayı desteklemesi amacıyla bakılan MPV(Ortalama Trombosit Hacmi), Nötrofil-lenfosit Oranı(NLO), Platelet-Lenfosit Oranı(PLO) ve (Sistemik immün-inflamasyon indeksi)Sİİ değerleri ise her iki hastalıkta atak ve remisyonu göstermede etkili parametreler olarak görüldü.
Sonuç: Çalışmamızda HDL/Ürik Asit oranı ile inflamatuar barsak hastalıklarında hasta kontrol grupları arasında anlamlı fark saptanmadı (p>0,05). Literatürde İBH ile HDL/Ürik Asit arasında yapılan bir çalışma olmadığından karşılaştırma yapılamadı. Daha önce yapılan çalışmaların metabolik hastalıklar ile anlamlı çıkmasından dolayı bu parametrenin
v
inflamasyon ile seyreden hastalıklardan ziyade metabolik yol üzerinden gelişen hastalıklarda daha anlamlı çıkacağı öngörülmüştür.
Objective: It is aimed to study the HDL/Uric acid ratio as an indicator of poor metabolic status in inflammatory bowel diseases. Method: In our study, patients with a diagnosis of IBD and patients who did not have any additional disease and applied with functional complaints were included who applied to the Necmeddin Erbakan University Meram Medical Faculty gastroenterology clinic and general internal medicine clinic between July 2021 and May 2022. Patients were retrospectively screened for sociodemographic characteristics, clinical and laboratory parameters. Results: A total of 200 participants, 72 with ulcerative colitis (UC), 26 with crohn's and 102 without inflammatory bowel disease, were included in the study. 56.10% (n=55) of the patients and 43.10% (n=44) of the control group were male. The mean age of the patients was 41.52 ± 13.95 years, and 38.62 ± 14.20 years in the control group. The distribution of gender, age and body mass index (BMI) was statistically similar between ulcerative colitis, crohn's and control groups (p>0.05). It was determined that 76.50% (n=72) of the patient group were in remission and 23.50% (n=23) were aktive. Disease duration was determined as 6.87 ± 5.18 years in UC patients and 6.30 ± 3.90 years in Crohn's patients. 29.60% (n=29) of the patients had active complaints. 2.80% (n=2) of UC patients and 30.80% (n=8) of Crohn's patients had a history of surgery. There was no statistically significant difference in HDL/Uric Acid ratio between the patient and control groups, and the attack and remission groups (p>0.05). MPV (Mean Platelet Volume), Neutrophil-Lymphocyte Ratio (NLR), Platelet-Lymphocyte Ratio (PLO) and (Systemic immune-inflammation index) SII values, which were measured to support the study, were found to be effective parameters in demonstrating relapse and remission in both diseases. Conclusion: In our study, no significant difference was found between HDL/Uric Acid ratio and patient control groups in inflammatory bowel diseases (p>0.05). Since there is no study in the literature between IBD and HDL/Uric Acid, a comparison could not be made. Since previous studies were found to be significant with metabolic diseases, it was predicted that this parameter would be more significant in diseases that developed through the metabolic pathway rather than diseases progressing with inflammation.
Objective: It is aimed to study the HDL/Uric acid ratio as an indicator of poor metabolic status in inflammatory bowel diseases. Method: In our study, patients with a diagnosis of IBD and patients who did not have any additional disease and applied with functional complaints were included who applied to the Necmeddin Erbakan University Meram Medical Faculty gastroenterology clinic and general internal medicine clinic between July 2021 and May 2022. Patients were retrospectively screened for sociodemographic characteristics, clinical and laboratory parameters. Results: A total of 200 participants, 72 with ulcerative colitis (UC), 26 with crohn's and 102 without inflammatory bowel disease, were included in the study. 56.10% (n=55) of the patients and 43.10% (n=44) of the control group were male. The mean age of the patients was 41.52 ± 13.95 years, and 38.62 ± 14.20 years in the control group. The distribution of gender, age and body mass index (BMI) was statistically similar between ulcerative colitis, crohn's and control groups (p>0.05). It was determined that 76.50% (n=72) of the patient group were in remission and 23.50% (n=23) were aktive. Disease duration was determined as 6.87 ± 5.18 years in UC patients and 6.30 ± 3.90 years in Crohn's patients. 29.60% (n=29) of the patients had active complaints. 2.80% (n=2) of UC patients and 30.80% (n=8) of Crohn's patients had a history of surgery. There was no statistically significant difference in HDL/Uric Acid ratio between the patient and control groups, and the attack and remission groups (p>0.05). MPV (Mean Platelet Volume), Neutrophil-Lymphocyte Ratio (NLR), Platelet-Lymphocyte Ratio (PLO) and (Systemic immune-inflammation index) SII values, which were measured to support the study, were found to be effective parameters in demonstrating relapse and remission in both diseases. Conclusion: In our study, no significant difference was found between HDL/Uric Acid ratio and patient control groups in inflammatory bowel diseases (p>0.05). Since there is no study in the literature between IBD and HDL/Uric Acid, a comparison could not be made. Since previous studies were found to be significant with metabolic diseases, it was predicted that this parameter would be more significant in diseases that developed through the metabolic pathway rather than diseases progressing with inflammation.
Açıklama
Anahtar Kelimeler
İnflamatuar barsak hastalıkları, Ülseratif kolit, Crohn hastalığı, HDL/Ürik Asit oranı, Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease, HDL colesterol to Uric Acid ratio
Kaynak
WoS Q Değeri
Scopus Q Değeri
Cilt
Sayı
Künye
Doğan. K. (2022). İnflamatuar barsak hastalıklarında kötü metabolik durum göstergesi olarak HDL/ürik asit oranının değerlendirilmesi. (Yayınlanmamış tıpta uzmanlık tezi) Necmettin Erbakan Üniversitesi, Meram Tıp Fakültesi DahiLİ Tıp Bilimleri Bölümü İç Hastalıkları Anabilim Dalı, Konya.
